当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Teesha Arora and David Wright
Lemierre’s syndrome (postanginal septicaemia/human necrobacillosis) was first defined and described in 1936 by Lemierre, a French Physician and Professor in Microbiology, although the first case report of human necrobacillosis was published in 1900 by Courmont and Cade [1,2]. Lemierre’s syndrome has come to be known as the “forgotten” disease, as very few cases have been reported since the introduction and widespread use of antibiotics [3,4]. In the preantibiotic era, Lemierre’s Syndrome was associated with a mortality rate of approximately 90% [1]. Currently, the associated mortality rate is estimated to range from 5% to 10% [5-7]. Since 1974, less than 100 cases have been reported [8,9]. This can be explained by the fact that more throat infections received early treatment with the widespread use of antibiotics, leading to the decrease in the incidence of Lemierre’s disease. The syndrome is characterised by a recent history of oropharyngitis with persistent fevers, followed by septic thrombophlebitis of the internal jugular vein and dissemination of the infection to multiple sites distant to the pharynx [10]. Fusobacterium species are responsible in most cases. It affects previously healthy adolescents and young adults.